Orchestra BioMed Holdings, Inc.
OBIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $3 | $4 | -$1 |
| % Growth | -4.4% | -21.9% | 551.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $2 | $3 | $3 | -$1 |
| % Margin | 92.3% | 93.3% | 90.9% | 125.4% |
| R&D Expenses | $43 | $34 | $22 | $13 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $24 | $20 | $14 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $67 | $54 | $36 | $21 |
| Operating Income | -$64 | -$52 | -$33 | -$22 |
| % Margin | -2,437.5% | -1,866.2% | -924.3% | 2,787.6% |
| Other Income/Exp. Net | $3 | $2 | -$1 | -$1 |
| Pre-Tax Income | -$61 | -$49 | -$34 | -$23 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$61 | -$49 | -$34 | -$23 |
| % Margin | -2,313.3% | -1,779.7% | -951.3% | 2,943% |
| EPS | -1.66 | -1.48 | -1.32 | -0.019 |
| % Growth | -12.2% | -12.1% | -7,035.1% | – |
| EPS Diluted | -1.66 | -1.48 | -1.32 | -0.019 |
| Weighted Avg Shares Out | 37 | 33 | 25 | 20 |
| Weighted Avg Shares Out Dil | 37 | 33 | 25 | 20 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $4 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$64 | -$51 | -$32 | -$22 |
| % Margin | -2,425.8% | -1,855.8% | -918.1% | 2,764.5% |